Meta AnalysisID 7236
α-硫辛酸补充剂治疗非酒精性脂肪性肝病：系统评价和Meta分析
CRD42023427856
Alpha lipoic acid efficacy for management of NAFLD versus placebo.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7236
- Evidence Id
- 15794
- Core Evidence Id
- 15794
- Source Meta Analysis Id
- 7222
- Herb2 Meta Analysis Id
- HBMA007222
- Crd Id
- CRD42023427856
- Title
- Alpha-lipoic Acid Supplementation for Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis
- Review Question
- Alpha lipoic acid efficacy for management of NAFLD versus placebo.
- Study Type Included
- We will include randomized control trials to assess the beneficial effects of Alpha lipoic acid.
- Condition Being Studied
- Alpha-lipoic acid (ALA) is a short-chain fatty acid known for its antioxidant properties. Some studies suggest that ALA may be used as an anti-inflammatory supplement in the setting of NAFLD, however data is largely limited to animal models and is notably contradictory. While some studies demonstrate improvement in inflammatory markers with the use of ALA , others report neutral effects of the supplement. Therefore, it is difficult to conclude whether or not ALA should be regularly prescribed to patients diagnosed with NAFLD. We will plan to investigate the efficacy of Alpha lipoic acid in NAFLD.
- Participant
- Inclusion criteria: 1.RCTs that investigated the effects of alpha-lipoic acid on NAFLD patients (All patients) 2. Studies that used alpha-lipoic acid as a monotherapy. 3. Studies that reported outcomes such as changes in liver function tests, insulin resistance, body weight, and other relevant clinical endpoints. 4. Studies that were published in peer-reviewed journals in the English language. Exclusion criteria: 1. Studies that were conducted on animals or in vitro models. 2. Studies that used alpha-lipoic acid as a part of a combination therapy without a control group that received the same therapy without alpha-lipoic acid. 3. Studies that reported incomplete data or lacked appropriate statistical analyses. Abstracts only and letters to editors 4. Observations studies ( Case-control, case series, case reports, Cross-sectional studies, cohort studies) 5. Studies that were not published in the English language.
- Animal
- Human Disease Modelled
- Intervention
- Alpha lipoic acid supplementation in patients with NAFLD vs Placebo. Intervention: Alpha lipoic acid (ALA) supplementation. Comparison: Placebo or no treatment.
- Comparator Control
- Comparison: Placebo or no treatment.
- Main Outcome
- 1. Liver enzymes (AST/ALT) 2. Insulin resistance (Insulin level, Fasting blood sugar, QUICKI score) 3. Anthropometrics ( Weight, Body mass index (BMI), Waist circumference (WC), Hip circumference (HC), Fat mass (FM), Visceral fat ( VF). Measures of effect Mean Difference
- Outcome Measure
- Additional Outcome
- None Measures of effect Not applicable
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Dietary Supplements; Humans; Non-alcoholic Fatty Liver Disease; Thioctic Acid
- Contact
- Islam Mohamed [email protected]
- Organisational Affiliation
- University of Missouri-Kansas city
- Funding Source
- Not applicable
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Not applicable
- Published Protocol
- Review Type
- Language
- English
- Country
- Egypt, United States of America
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-05-19
- Registration Date
- 2023-05-31
- Anticipated Start Date
- 2023-04-01
- Anticipated Completion Date
- 2023-06-30
- Title Cn
- α-硫辛酸补充剂治疗非酒精性脂肪性肝病：系统评价和Meta分析
- Title En
- Alpha-lipoic Acid Supplementation for Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis
- Bilingual Status
- complete